Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment

NCT06663787 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer, Metastatic
HER2 + Breast Cancer

Interventions

DRUG: Trastuzumab (Herceptin)
DIAGNOSTIC_TEST: SIgnatera

Sponsor

Nagoya City University